# Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

> **NCT04665050** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 102 (actual)

## Conditions studied

- Pneumococcal Infection

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** PNEUMOVAX™23

## Key facts

- **NCT ID:** NCT04665050
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-04
- **Primary completion:** 2021-04-06
- **Final completion:** 2021-04-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665050, "Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04665050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*